Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
A quality compounder is a business that not only sports durable competitive advantages but also builds on its success by consistently reinvesting its profits...
PINK outperformed XLV by 8.7 percentage points over one year, but carries higher fees and volatility. XLV offers lower costs and a higher dividend yield for passive healthcare exposure.
Vanguard's broad sector approach costs half as much and yields twice the dividend, while Invesco's biotech focus delivered stronger 1-year returns but with steeper downside risk.
PPH targets drugmakers exclusively with higher returns but steeper costs, while XLV diversifies across medical equipment and providers at a fraction of the fee.
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...
VanEck's concentrated biotech portfolio surged 30.8% in one year but endured a 39.9% drawdown. iShares offers steadier global healthcare exposure with a 1.5% dividend yield.
The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider healthcare sector. The choice comes down to whether to lean into pharma-driven returns or take a broader approach to global healthcare.
